<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, +16

Science

Preexistence and Clonal Selection of MET Amplification in EGFR Mutant NSCLC

Alexa B. Turke, Kreshnik Zejnullahu, Yi‐Long Wu, +18

Cancer Cell

Signal TransductionMet AmplificationMedicineMolecular BiologyEgfr Mutant Nsclc +4

<i>EML4-ALK</i> Fusion Gene and Efficacy of an ALK Kinase Inhibitor in Lung Cancer

Jussi Koivunen, Craig H. Mermel, Kreshnik Zejnullahu, +17

Clinical Cancer Research

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with <i>EGFR</i> and <i>ERBB2</i> Mutations that Are Resistant to Gefitinib

Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, +15

Cancer Research

Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab

Kimio Yonesaka, Kreshnik Zejnullahu, Isamu Okamoto, +29

Science Translational Medicine

Cetuximab SensitivityOncologyErbb2 SignalingSignaling PathwayMedicine +13

Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer

J. A. Engelman, Toru Mukohara, Kreshnik Zejnullahu, +13

Journal of Clinical Investigation

EngineeringEgfr-amplified Lung CancerPathologyCancer BiologyTumor Biology +18

Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins

William W. Lockwood, Kreshnik Zejnullahu, James E. Bradner, +1

Proceedings of the National Academy of Sciences

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Dalia Ercan, Kreshnik Zejnullahu, Kimio Yonesaka, +10

Oncogene

Molecular PharmacologyTumor BiologyEgfr T790mCancer GrowthCell Biology +5

Evidence that synthetic lethality underlies the mutual exclusivity of oncogenic KRAS and EGFR mutations in lung adenocarcinoma

Arun M. Unni, William W. Lockwood, Kreshnik Zejnullahu, +2

eLife

Human Lung AdenocarcinomasLung AdenocarcinomaPathologySynthetic LethalityCancer Biology +20

Resistance to Irreversible EGF Receptor Tyrosine Kinase Inhibitors through a Multistep Mechanism Involving the IGF1R Pathway

Alexis B. Cortot, Claire E. Repellin, Takeshi Shimamura, +7

Cancer Research

Kinase InhibitorsPharmacotherapyTumor BiologyDrug ResistanceSignaling Pathway +15